- Home
- INCY vs MDB Comparison
INCY vs MDB Comparison
Compare INCY & MDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- MDB
- Stock Information
- Founded
- INCY 1991
- MDB 2007
- Country
- INCY United States
- MDB United States
- Employees
- INCY N/A
- MDB N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- MDB Computer Software: Prepackaged Software
- Sector
- INCY Health Care
- MDB Technology
- Exchange
- INCY Nasdaq
- MDB Nasdaq
- Market Cap
- INCY 13.4B
- MDB 15.6B
- IPO Year
- INCY 1993
- MDB 2017
- Fundamental
- Price
- INCY $65.06
- MDB $188.83
- Analyst Decision
- INCY Hold
- MDB Buy
- Analyst Count
- INCY 19
- MDB 30
- Target Price
- INCY $72.67
- MDB $290.27
- AVG Volume (30 Days)
- INCY 1.8M
- MDB 2.2M
- Earning Date
- INCY 04-29-2025
- MDB 06-04-2025
- Dividend Yield
- INCY N/A
- MDB N/A
- EPS Growth
- INCY N/A
- MDB N/A
- EPS
- INCY 0.10
- MDB N/A
- Revenue
- INCY $4,413,226,000.00
- MDB $2,006,443,000.00
- Revenue This Year
- INCY $13.29
- MDB $14.48
- Revenue Next Year
- INCY $10.43
- MDB $16.54
- P/E Ratio
- INCY $592.09
- MDB N/A
- Revenue Growth
- INCY 17.13
- MDB 19.22
- 52 Week Low
- INCY $53.56
- MDB $140.78
- 52 Week High
- INCY $83.95
- MDB $370.00
- Technical
- Relative Strength Index (RSI)
- INCY 60.01
- MDB 56.35
- Support Level
- INCY $63.51
- MDB $182.90
- Resistance Level
- INCY $66.26
- MDB $191.73
- Average True Range (ATR)
- INCY 1.60
- MDB 5.30
- MACD
- INCY 0.32
- MDB 0.15
- Stochastic Oscillator
- INCY 83.12
- MDB 39.59
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About MDB MongoDB Inc.
Founded in 2007, MongoDB is a vendor of a document-oriented database that accelerates development processes of new applications. Enterprise customers can choose between the fully managed offering, MongoDB Atlas, or the self-managed version, MongoDB Enterprise Advanced. MongoDB is a popular tool among developers, and its free Community Server has recorded over 500 million downloads since 2009.